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Abstract 
Sexual problems are associated with greater depression, body change stress, and worse mental 
health quality-of-life in women who have survived cancer (Levin, Carpenter, Brothers, et al., 
2010). Despite a number of studies of sexual activity and function in survivors of cancer, little is 
known about the natural course of resumption and maintenance of sexual activity following 
cancer diagnosis and treatment. This project tests the hypothesis that the presence of sexual 
activity during treatment will predict better sexual function and satisfaction scores at 4 months 
post treatment initiation when controlling for demographic, disease, psychosocial, and baseline 
sexual function. Patients (N=79) undergoing adjuvant chemotherapy completed questionnaires 
prior to, throughout, and 4-months after beginning treatment. In regression analyses, sexual 
activity predicted desire and arousal at 4 months, however higher satisfaction scores was not 
associated with sexual activity during treatment. Analyses predicting orgasm did not converge 
and therefore results were uninterpretable. The relationship between sexual activity and sexual 
satisfaction is complex and highly personal and more research is needed to understand better 
predictors of satisfaction. Results suggest that encouraging sexual activity may protect against 
loss in sexual function during adjuvant therapy. Providers are encouraged to have discussions 
with patients about their sexual lives alongside other quality-of-life concerns and to offer 
resources, if needed.  
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Introduction 
Breast and gynecologic cancers are common, accounting for around 40% of new cancer 
diagnoses in women (Siegel, Miller, & Jemal, 2016). While treatments for these cancers have led 
to increased survival rates, these very same treatments are known to lead to side effects that may 
be physically and emotionally debilitating. In particular, survivors of breast and gynecologic 
cancers are more prone to sexual problems when compared to other cancer survivor groups, as 
well as healthy controls (Bober & Varela, 2012; Boquiren et al., 2016). The aims of the present 
study are to determine rates of sexual activity during adjuvant therapy in a sample of breast and 
gynecologic cancer patients and to test examine the relationship between engagement in sexual 
activity and sexual function and satisfaction. To begin, an explanation of the treatment of breast 
and gynecologic cancer is given, followed by an overview of the literature regarding side effects, 
with a focus on sexual morbidity, following a cancer diagnosis. The overview concludes with a 
discussion of the theoretical rationale of examining sexual activity as a predictor of sexual 
function and satisfaction.  
There is a large range of potential treatments for breast and gynecologic cancer. Surgical 
treatment is often the first treatment offered, with secondary, or adjuvant, therapies to follow. 
Breast cancer patients may undergo breast-conserving surgery (i.e., lumpectomy), removing 
cancer tissue without removing the entire breast, or a full mastectomy, where all breast tissue is 
removed. Radical mastectomy is the most extensive surgical treatment, with surgeons removing 
all breast tissue, surrounding lymph nodes, and underlying pectoral muscles (Chang, Haigh, & 
Giuliano, 2005). Patients who have undergone mastectomy are able to receive reconstructive 
surgery through using their own body tissues (i.e., tissue flap procedures) or through breast 
implants made of saline or silicone. Additionally, nipple/areola tattooing and fat grafting are 
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available to reconstruct the surface of the breast, although the reconstructed nipple will have no 
sensation (American Cancer Society, 2017). 
Gynecologic cancer surgeries vary widely based on stage and diagnosis, with the most 
common surgeries including oophorectomy, or removal of one or more ovaries, and 
hysterectomy, which may include a partial or total removal of the uterus and surrounding 
connective tissues and structures, including the cervix and parts of the vagina (Berek & Hacker, 
2005). For vulvar malignancies, partial or total removal of the vulvar structures, or vulvectomy, 
may be necessary (Berek & Hacker, 2005).  
 Adjuvant therapies are common and are meant to attack cancerous cells left behind by 
surgery. Common adjuvant therapies for breast and gynecologic cancer include radiation 
therapy, hormonal therapy, and chemotherapy (Berek & Hacker, 2005). Chemotherapy is the use 
of drugs to kill cancerous cells. Unfortunately, these drugs cannot differentiate between fast-
growing cancer cells and fast-growing healthy cells. Thus, healthy cells are harmed along with 
the cancer, leaving many people undergoing chemotherapy with side effects. The most common 
side effects for cancer patients undergoing chemotherapy include fatigue, hair loss, easy bruising 
and bleeding, infection, anemia, nausea and vomiting, appetite changes, constipation, diarrhea, 
nerve problems, and more (American Cancer Society, 2016; Berek & Hacker, 2005). 
Side effects of treatment may lead to high rates of sexual morbidity in these women 
(Berek & Hacker, 2005). While cancer treatment can produce quality of life concerns in many 
cancer survivor groups, the nature of breast and gynecologic cancers make them more prone to 
sexual concerns than other cancer groups (Bober & Varela, 2012). Gynecologic patients, in 
particular, often experience damage to pelvic and vaginal nerves and tissues due to targeted 
treatment in and around these areas (Pieterse et al., 2006; Wilmoth & Botchway, 1999). Breast 
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cancer surgeries often leave patients with changes in sensation in the breasts as well as body 
image disruption due to potentially disfiguring surgeries (G. M.  Frierson & Andersen, 2006; G. 
M. Frierson, Thiel, & Andersen, 2006). In both breast and gynecologic patient groups, treatments 
often induce menopause.  Due to the associated reduction in hormones, including estrogen, 
progesterone, and testosterone, menopause is associated with sexual problems including vaginal 
dryness, dyspareunia, and lack of sexual interest in both healthy women and cancer survivors 
(Lee, Kim, & Jeon, 2015; McCoy & Davidson, 1985). The effects of treatment-induced 
menopause are known to create a feedback loop wherein sexual pain may induce a lack of 
interest in sex, and over time, vaginal atrophy occurs, making sexual activity more 
uncomfortable if it is attempted again (Bober & Varela, 2012). Further, even side effects that do 
not initially appear to be related to sexual function may in fact contribute to a patient’s function, 
satisfaction, and desire for sexual activity. For example, heightened anxiety, nausea and 
vomiting, fatigue, pain and confusion or “chemobrain”, are all reported widely in female cancer 
patients (Levin, Carpenter, & Andersen, 2010). Using DSM IV criteria, as many as 23 percent of 
gynecologic cancer patients may qualify for major depressive disorder (Thompson & Shear, 
1998). Given these unpleasant physical and emotional symptoms, it is unsurprising that women 
undergoing treatment may find themselves not wanting or enjoying sexual activity. 
Among survivors of breast and gynecologic cancers, there are high rates of sexual 
dysfunction. Under DSM IV criteria, four domains of female sexual function were addressed: 
desire disorders, arousal disorders, orgasmic disorders, and pain disorders (Zakhari, 2009). 
Under DSM 5 criteria, female sexual dysfunction is represented over three disorders: female 
sexual interest/arousal disorder, female orgasmic disorder, and genito-pelvic pain/penetration 
disorder (American Psychiatric Association, 2013). However, in the available literature, 
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diagnostic interviews are seldom conducted to assess whether cancer patients meet criteria for a 
diagnosable sexual dysfunction. Rather, patients are asked to self-report individual sexual 
problems, generally grouped into desire, orgasm, arousal/lubrication, and pain. Overall, survivors 
report some level of sexual problems at rates between 70-80% (Boquiren et al., 2016; Raggio, 
Butryn, Arigo, Mikorski, & Palmer, 2014). This suggests a much higher rate of dysfunction than 
in the general population, who are estimated to experience sexual problems at a rate of 
approximately 40-45% (Laumann, Paik, & Rosen, 1999; Lewis et al., 2010). Among cancer 
survivors, the most highly endorsed sexual difficulty is desire, with many survivors reporting 
multiple problems (Boquiren et al., 2016; Grimm et al., 2015; Lee et al., 2015; Marino, 
Saunders, & Hickey, 2017). 
In a cross-sectional study of 186 gynecologic cancer survivors between 2-10 years post-
diagnosis, sexual problems after cancer are associated with other psychosocial problems, 
including depression, body change stress, and mental health quality of life (Levin, Carpenter, 
Brothers, et al., 2010). In regression analyses, sexual morbidity covaries with depressive 
symptoms, body change stress, and poorer psychological quality of life when controlling for age, 
performance status (well-being and ability to accomplish daily activities), and fatigue (Levin, 
Carpenter, Brothers, et al., 2010). Such cross-sectional studies are limited in that causality cannot 
be addressed, however, this study suggests that there is a relationship between psychological 
quality of life and sexual problems. This is supported in the sexual health literature; sexual 
problems are consistently shown to be associated with depression, anxiety, and relationship 
problems (Atlantis & Sullivan, 2012; Dunn, Croft, & Hackett, 1999; Shifren, Monz, Russo, 
Segreti, & Johannes, 2008). 
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 Following treatment, approximately 30-60% of breast and gynecologic cancer survivors 
are sexually inactive (Grimm et al., 2015; Lee et al., 2015; Marino et al., 2017; Raggio et al., 
2014). While sexual problems and inactivity are also common in healthy post-menopausal 
women, the proportion is smaller and reasons for becoming sexually inactive tend to differ 
between the groups (Grimm et al., 2015; Marino et al., 2017). In sexually inactive women 
without a cancer history, the most common reason for sexual inactivity reported is not having a 
partner, while in survivors of gynecologic cancer, physical problems were the most commonly 
cited reason, suggesting that treatment effects are more severe than natural menopause (Grimm 
et al., 2015). Among women who were sexually active before diagnosis with breast cancer, 
approximately 10% do not resume sexual activity (Lee et al., 2015). In self-reports, the majority 
of partnered women who become inactive following cancer attribute the change to internal (e.g. 
pain, vaginal dryness, lack of interest, fatigue) versus external (e.g., partner) factors (Marino et 
al., 2017). This suggests that problems including sexual dysfunction and other side effects from 
cancer and its treatments may be important contributors to sexual inactivity. 
In an Australian study of partnered female cancer survivors (n=316), investigators found 
that inactivity was associated with feelings of unattractiveness, feeling unlike a woman, and 
depressive symptoms (Marino et al., 2017). In studies of the general population, sexual inactivity 
in partnerships has shown to be associated with lower happiness in their relationship, less social 
support, and poorer health (Donnelly, 1993; Hess et al., 2009; Karraker & DeLamater, 2013). 
The Survey of Midlife Development, a survey of a representative sample of adults in the United 
States, found that sexually inactive women reported lower satisfaction (Thomas, Hess, & 
Thurston, 2015), a finding that was also reported in Marino et al.’s study of partnered female 
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survivors (2017). Thus, while sexual inactivity may serve as a useful indicator of sexual 
problems, relationship difficulties, and related distress in cancer survivors. 
Overall, data from survivors of cancer show that treatment can greatly affect their sexual 
lives. However, there is little known about the sexual lives of women in active treatment. Many 
women avoid sexual activity during active treatment due to acute side effects, but it is unclear 
what is unique about women who maintain sexual activity. To our knowledge, there are no 
studies examining the natural course of resumption of sexual activity following initiation of 
adjuvant chemotherapy. By understanding the circumstances under which individuals 
successfully resume or maintain sexual activity during the course of treatment, we may also 
begin to understand if and when sexual inactivity can be regarded as problematic, rather than a 
healthy reaction to the acute stresses of cancer diagnosis and treatment.  
The aims of this study are to (1) estimate rates of sexual activity during adjuvant therapy 
in a sample of breast and gynecologic cancer patients; (2) test sexual activity during adjuvant 
chemotherapy as a predictor of 4-month sexual outcomes (sexual satisfaction, sexual function). 
Our hypothesis is that the presence of sexual activity during treatment will predict better sexual 
outcomes at four months. Depressive symptomology, relationship satisfaction, and patient-
reported treatment toxicities (e.g., pain, menopausal symptoms, fatigue) are all examined as 
possible covariates, alongside relevant sociodemographic variables. These variables served as 
controls in our analyses due to existing literature suggesting that sexual problems and emotional 
problems are related (Atlantis & Sullivan, 2012; Dunn et al., 1999; Shifren et al., 2008). 
Unpleasant symptoms, including physical pain, emotional distress, and partner problems may 
negatively affect women’s engagement in and enjoyment of sexual activity, thus we account for 
these variables in our analyses. 
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Method 
We used a prospective, longitudinal design with repeated measures. Participants (N=80) 
are female patients with gynecologic or breast cancer treated in the Division of Gynecologic 
Oncology or the Division of Medical Oncology at the Ohio State University Comprehensive 
Cancer Center. Participants were accrued following surgery (as applicable) and prior to 
beginning chemotherapy. Assessments occurred at baseline (prior to initiation of chemotherapy); 
at the beginning of each chemotherapy cycle, up to six cycles, on the day of infusion, and four 
months after beginning treatment. The protocol was approved by the Ohio State University’s 
Institutional Review Board.  
Measurement  
Data from subjects include interview responses, self-report inventories, relevant medical 
chart data (e.g., diagnosis, treatments), and medical evaluations. Sociodemographic information 
(e.g., household income, education, employment status, etc.) was obtained from patients via 
interview.  
Sexual Outcomes. Sexual activity, as well as sexual function and satisfaction, was 
assessed using 11 self-report items. Behaviors (frequency of kissing and intercourse) and global 
satisfaction items were taken from the Sexual Experiences Scale (Derogatis & Meyer, 1979) and 
are used to assess the range and frequency of sexual activity. Women are asked to rate the 
frequency of intimate and affectionate behaviors (e.g., intercourse, kissing) in the past month (at 
baseline) or since the last assessment (at all follow-ups). We assessed sexual function self-reports 
of the presence/absence of sexual activity, sexual avoidance, desire, vaginal dryness, lubrication 
during intercourse, orgasm, and dyspareunia. The present study focuses on sexual activity, 
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desire, arousal, orgasm, and satisfaction. These items are worded appropriately to assess both 
heterosexual and lesbian relationships.  
Depressive Symptoms. The Iowa short-form of the Center for Epidemiological Studies 
Depression Scale (CES-D) (Kohout, Berkman, Evans, & Cornoni-Huntley, 1993) was used to 
assess current symptoms of depression. This short form consists of 11 items rated on 3-point 
Likert scales from 0=hardly ever or never to 2=much or most of the time. Unique to other 
measures of depressive symptoms, the CES-D is relatively unaffected by current physical 
symptoms and is, therefore, commonly used in research on medical populations (Devins, Orme, 
Costello, & Binik, 1988).  
Treatment Toxicities. A patient-reported subset of the NCI common toxicity criteria, 
v4.0, was used. The Patient-Reported Outcomes CTCAE (PRO-CTCAE) version 1 (Basch & 
Abernethy, 2011; Basch et al., 2012; Basch et al., 2007; Basch et al., 2006), allows patients to 
self-report symptomatic adverse events. Items are grouped within body categories. Subscale 
scores are calculated to reflect the average of items for each body system; scores range from 0-4, 
with higher scores indicating more life-threatening symptoms. Subscores can be obtained for 
frequency, severity, and interference of symptoms.  We opted to include the interference scores 
in regression analyses, as it seemed the most relevant in controlling for effect on sexuality. 
Procedures 
Patient charts were reviewed by study staff to identify eligibility. Patients were diagnosed 
with stage I-III breast or gynecologic cancer and be scheduled to receive adjuvant chemotherapy. 
Patients with a prior cancer diagnosis (i.e., women with recurrence) were excluded. Patients were 
required to be between the ages of 21 and 80 and not have any major psychiatric illness or 
cognitive deficit that would impact their ability to complete the interview. At a clinic visit prior 
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to their first chemotherapy infusion, patients were approached by a research staff member and 
told about the study. If they indicated interest, informed consent was obtained. Questionnaires 
were then administered by the staff member, who was responsible for marking the participant’s 
verbal responses to the questions. Whenever possible, assessments were completed in full during 
a clinic visit. When time or distance did not allow, participants were asked to complete the 
questionnaires over the phone or via mail. Patients were paid $35 for each full assessment, as 
well as $15 for each brief assessment during chemotherapy infusions. 
Eighty participants were consented into the study. One participant experienced severe 
side effects to her first infusion of chemotherapy, which began between consent and the 
beginning of assessment, and thus did not complete any questionnaires. Of the 79 participants 
who completed at least some of the baseline assessment, 72 (91%) completed the 4-month 
follow-up, with the remainder lost to follow-up.   
Analysis 
Data from baseline (prior to first chemotherapy infusion) assessment and from four 
months are analyzed. Descriptive data characterize the sample at baseline and 4-months and 
include sociodemographics, diagnosis, treatment toxicity, depressive symptoms, and sexual 
function and satisfaction. Baseline and 4-month scores in sexual outcomes of activity, desire, 
arousal, orgasm, and satisfaction are compared to examine any differences. Differences in means 
of sexual outcomes at 4 months by diagnosis type (breast cancer vs. gynecologic cancer) are 
examined. Participants were categorized into either sexually “active” or “inactive” categories 
based on their responses to the sexual activity items administered at baseline, chemotherapy 
infusion visits, and 4-month follow-up. If at any of these assessments, the participant reported 
some sexual activity, they are categorized as “sexually active.” We examined between-group 
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(sexually active vs. inactive) differences in sexual outcomes and covariates. Correlations 
between baseline measures and 4-month sexual outcomes are reported. 
Regression analysis will be used to examine variance in 4-month sexual outcomes. 
Functional outcomes were dichotomous, and thus will be analyzed using logistic regression. 
Satisfaction was measured with a continuous Likert scale and will be analyzed using multiple, 
hierarchical linear regression. For all regressions, the first step will include baseline 
sociodemographic factors (age, partner status). In the desire model, diagnosis was also added in 
Step 1 to control for a mean difference in desire between breast and gynecologic diagnosis 
groups. Due to the fact that diagnosis groups did not differ in any other outcomes, it was omitted 
from the other models. Step 2 will include baseline depressive symptoms.  Step 3 will include 
disease- and treatment- related variables (e.g., 4-month  treatment toxicity). Step 4 will control 
for baseline score on the specific outcome (e.g., baseline desire is controlled for when predicting 
4-month desire). In step 5, we test whether sexual activity during treatment was associated with 
better sexual function or satisfaction above and beyond these other variables.  
Results 
Sociodemographics can be found in Table 1. Descriptive statistics of all relevant 
physical, psychosocial, and sexual variables at baseline and 4 months can be found in Table 2. 
Pearson correlations were run between controls and sexual outcomes at baseline, and sexual 
outcomes at 4-month follow-up (Table 3).  
 At baseline, 27% of participants reported activity in the last month, while at 4 months, 
25% of the participants reported activity in the last month.  Using our criteria described above, 
43% of the sample was sexually active. 
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 In order to explore group differences based on diagnosis (breast vs. gynecologic cancer), 
independent sample t-tests were run with the outcome variables at 4-months (Table 4). 
Difference in sexual desire was trending towards significance and thus was included as an 
additional control variable in the regression. Otherwise, breast and gynecologic patients were 
collapsed for the subsequent analyses. 
 We examined change in sexual activity and sexual outcomes (function, satisfaction) over 
time (baseline vs. 4-months) using paired sample t-tests (Table 5). Overall, the rates of sexual 
activity and of sexual function in the sample did not change significantly over the 4 months. 
Similarly, the mean sexual satisfaction did not significantly change. 
Differences between active and inactive groups in sexual satisfaction and function were 
explored through independent sample t-tests (Table 5). These analyses revealed that differences 
between active and inactive in all outcomes were statistically significant. The group that engaged 
in sexual activity at some point during treatment reported experiencing sexual desire, arousal, 
and orgasm at 4-months more than the inactive group. Similarly, the active group reported higher 
levels of sexual satisfaction at 4-months.  
Logistic regression analyses were run for each dichotomous function outcome. Results 
showed that the model was significant for desire (χ2(7)=33.454, p<.001) and arousal 
(χ2(6)=31.717, p<.001) (Tables 7-8). Presence of sexual activity significantly predicted presence 
of sexual desire and arousal at 4-months. Due to low cell count, the model predicting orgasm did 
not converge and therefore results are uninterpretable.  
Linear regression analysis was run for the satisfaction variable. The model was 
significant [F(6, 60)=4.672, p=.001)] and predicted 32% of the variance in satisfaction (Table 9). 
However, sexual activity was not a significant unique predictor of higher sexual satisfaction. 
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Discussion 
The aims of this study were to (1) determine rate of sexual activity during adjuvant 
therapy in a sample of breast and gynecologic cancer patients; (2) test the presence of sexual 
activity, alongside relevant controls, as a predictor of sexual outcomes (function, satisfaction) 
during treatment. Our hypothesis is that the presence of sexual activity during treatment will 
predict greater desire, arousal, orgasm, and satisfaction scores at 4 months when controlling for 
demographic, disease, psychosocial, and baseline sexuality function. 
In terms of characterizing the sexual lives of the group, we found that 43% of the sample 
was sexually active at some point during treatment. There were no differences between groups 
(breast vs. gynecologic cancer) in sexual activity or sexual outcomes.  There were no significant 
differences in activity, desire, arousal, orgasm, or satisfaction rates over time (i.e., between 
baseline and 4-months), suggesting that rates of activity and function were stable across the first 
4 months of treatment. However, when separated into groups by activity, either sexually active 
or inactive, mean differences in all sexual outcome scores were significantly different, with the 
active group reporting better outcomes in desire, arousal, orgasm, and satisfaction. 
Our hypothesis was supported with regard to desire and arousal. Presence of sexual 
activity was associated with the presence of sexual desire and arousal at 4-months We are unable 
to draw conclusions regarding orgasm, an important domain of sexual functioning.  Due to low 
cell count, results from the model predicting orgasm did not converge and therefore results are 
uninterpretable. This issue, while problematic for regression analyses, makes conceptual sense as 
no sexually inactive participant reported experiencing orgasm. Sexual activity was not associated 
with better sexual satisfaction at 4-months. Thus, it appears that remaining sexually active during 
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treatment encourages better sexual function, but does not necessarily encourage more personal 
satisfaction with one’s sexual life.  
 High rates of desire may certainly encourage more activity because it is, by definition, 
desired by the woman. Similarly, higher rates of arousal may encourage more activity because 
response to sexual stimuli may provide physical pleasure and prevent sexual pain through the 
process of lubrication. However, given that our models controlled for baseline function, we can 
infer that beyond maintenance of pre-treatment sexuality, engaging in sexual activity during 
treatment is uniquely associated with enhanced desire and arousal at follow-up. This may be due 
to the fact that engagement in sexual activity may be protective against physical changes (e.g., 
vaginal atrophy). A lack of sexual activity may diminish desire over time and lead to vaginal 
atrophy, making future attempts at sexual activity potentially more painful and unpleasant, 
creating a difficult feedback loop (Bober & Varela, 2012). These results suggest that patients 
might benefit from engaging in sexual activity during treatment, even if she lacks sexual desire, 
in an effort to disrupt any feedback loop. Sex is not often discussed by oncology providers, even 
less so during active treatment (Kennedy et al., 2015; Sporn et al., 2015; Wiggins, Wood, Granai, 
& Dizon, 2007).  These results would suggest that such conversations could benefit patients as 
they transition out of treatment and into survivorship.  
While the total model was significant, sexual satisfaction was not significantly predicted 
by sexual activity. The relationship between sexual activity and sexual satisfaction is complex 
and highly personal, with nonsexual factors often holding high subjective importance (Frederick, 
Lever, Gillespie, & Garcia, 2017; Pascoal, Narciso, & Pereira, 2014; Velten & Margraf, 2017; 
Young, Denny, Luquis, & Young, 1998). While there is a subset of patients who are dissatisfied 
with their sexual inactivity, there is also a subset of patients who prefer to be inactive. In fact, 
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while no active participants reported that their sexual life “could not be better”, four inactive 
participants did (see Figure 1). While mean scores of satisfaction were significantly higher in the 
active group, there is a subset of the inactive group that is very satisfied with their lack of 
activity. This trend may be especially likely in older adult populations (Huang et al., 2009).  
Being sexually active does not guarantee better sexual function. While sexually active 
survivors report better physical quality of life, they also tend to report higher rates of sexual pain 
than those who are not engaging in sexual activity (Raggio et al., 2014). Further, previous studies 
have shown that levels of dissatisfaction in one’s sexual life are similarly high among both 
sexually active and inactive survivors (Marino et al., 2017; Raggio et al., 2014). Engagement in 
sexual activity may lead participants to be more acutely aware of treatment-related changes in 
sexual function, such as problems with lubrication and orgasm. 
While it is useful to know that engagement in sexual activity predict greater desire and 
arousal in a therapeutic context, sexual satisfaction is still an important outcome to consider. 
Patients who do not desire sex or do not experience arousal during sexual activity, but are 
perfectly satisfied with their sexual lives, are unlikely to seek treatment for sexual dysfunction, 
nor do they need to. There is normal variation in sexual activity and inactivity is not necessarily 
indicative of a problem. However, women who are sexually dissatisfied, regardless of their 
current level of activity, may seek help for these issues. There are a small group of behavioral 
interventions that have been tested for sexual morbidity after cancer (Brotto et al., 2012; 
Caldwell et al., 2003; Carpenter & Andersen, in prep). These interventions give multiple 
strategies to treat and cope with treatment-related sexual problems. Some, including vaginal 
dilators, moisturizers, and lubricants, address the physical problems that stem from treatment. 
Interventions often also include cognitive-behavioral therapy and mindfulness strategies. This 
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reassessment of automatic thoughts regarding sexuality may help to address expectations and 
dissatisfaction regarding one’s sexual life.  
Future directions in this study will include continuing follow-up with the participants. 
Data collection for 8-month and 12-month follow-ups is currently underway, and analysis may 
give more information regarding our models. This study was limited in that we did not collect 
sexual histories, nor did we collect data before primary cancer treatment (e.g., surgery). 
Collecting these earlier data may give a clearer picture of a true baseline, rather than after the 
patient had already experienced diagnosis and surgery. The sexual health questionnaire included 
in this study was very simple, as this was not the primary focus of the research. The items 
included were all dichotomous, posing a problem for analysis of findings, particularly in the 
domain of orgasm. The questionnaire could be improved through inclusion of continuous 
measures of sexual function. This adjustment would not only improve our ability to interpret 
results of the regression analysis, but would give a more complex picture of the experience of 
sexual function. Future research may expand on questions regarding sexual health, particularly 
satisfaction. An item asking about levels of distress alongside the question of quality of one’s 
sexual life may further elucidate the relationship between function, activity level, and 
satisfaction.  
Overall, this study lends some support to the idea that sexual activity may be important to 
maintaining sexual function after cancer, in the domains of desire and arousal. However, there is 
still much to learn in terms of sexual satisfaction and its predictors. In the meantime, the best 
method we have to identify sexual dissatisfaction and distress is to ask about it. Healthcare 
providers are highly encouraged to discuss sexual health with their patients, alongside other 
quality-of-life concerns, and to offer resources, if necessary. 
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Appendix 
 
Table 1. Descriptive characteristics of the sample  
 
Variable M / n SD / % 
Age 57.7 5.9 
Race*    
   Black 5 6.3% 
   White 73 92.4% 
   Native American 3 3.8% 
   Latino 2 2.5% 
Education    
   Obtained college degree 35 44.3% 
   Did not obtain college degree 44 55.7% 
Marital/Partnered Status   
   Single, never married 8 10.1% 
   Currently married 49 62% 
   Not married, but in a relationship 5 6.3% 
   Separated or divorced 13 16.5% 
   No longer married, widowed 4 5.1% 
Annual Household Income    
   <$25,000 9 11.4% 
   $25,000-$50,000 17 21.5% 
   $50,001-$100,000 24 30.4% 
   $100,001+ 22 27.8% 
   Don’t know/prefer not to answer 7 8.9% 
Cancer Type (n = 79)   
   Breast 38 48.1% 
   Endometrial/Uterine 23 29.1% 
   Ovarian 17 21.5% 
   Cervical 1 1.3% 
Received Surgery 76 96.2% 
 
*Participants were able to choose more than one racial identity 
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Table 2. Sexual outcome and control measure scores 
 
 Baseline 4-Month  
 M /n SD / % M/n SD/% Range 
Physical       
Treatment toxicity (PRO-CTCAE)       
      Interference Subscore  10.4 9.2 9.1 9.2 0-39 
Emotional/Psychological      
Depression (CES-D)  6.0 3.8 5.3 3.9 0-18 
Sexual Outcomes       
Sexually active  22 28.9% 20 28% - 
Experienced desire  37 49.3% 28 39% - 
Experienced arousal  30 37.5% 26 36% - 
Experienced orgasm  21 60% 18 75% - 
Experienced sexual pain  2 6.7% 8 40% - 
Sexual satisfaction 3.4 2.2 3.21 2.5 0-8 
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Table 3. Correlations Between Sexual Outcomes and Control Variables 
 
 Desire Arousal Orgasm Satisfaction 
Age -.146 -.108 -.138 .032 
College Education .261* .259* .129 -.064 
White -.069 -.087 .058 .026 
Partnered .058 .019 .120 .045 
Years w Partner -.248 -.205 -.143 -.069 
Family Income .142 .166 .267* .102 
Gynecologic Cancer -.216 -.158 -.032 .048 
Baseline Activity (Y/N) .351** .396** .324** .213 
Baseline Desire (Y/N) .519** .467** .454** .243* 
Baseline Arousal (Y/N) .547** .480** .470** .246* 
Baseline Orgasm (Y/N) .496** .496** .409* .423* 
Baseline Satisfaction  .279* .255* .333** .510** 
Relationship Satisfaction .118 .082 .061 .142 
Baseline CES-D -.285* -.221 -.197 -.256* 
4-Month PROCTCAE Interference -.109 -.073 -.101 -.141 
4-Month PROCTCAE Severity -.080 .030 -.031 -.122 
4-Month PROCTCAE Frequency -.084 .020 -.135 -.151 
 
   * Significant at the 0.05 level (2-tailed). 
** Significant at the 0.01 level (2-tailed). 
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Table 4. 4-Month Outcomes By Diagnosis Using t-test for Equality of Means 
 
 
 Breast Gynecologic   
 M SD M SD t-test p-value 
Active .32 .48 .24 .43 .81 .42 
Desire .50 .51 .29 .46 1.85 .07 
Arousal .44 .50 .29 .46 1.34 .19 
Orgasm .75 .45 .75 .45 .00 1.00 
Satisfaction 3.09  2.37  3.32   2.63 -.40 .69 
 
  *Significant at p<.05 (2-tailed) 
**Significant at p<.01 (2-tailed) 
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Table 5. Baseline and 4-Month Paired Sample Statistics 
     
 Baseline 4-Month   
 M SD M SD r t 
Activity .30 .50 .29 .46 -.34** .23 
Desire .51 .50 .41 .50 .52** 1.72 
Arousal .39 .49 .38 .49 -.48** .24 
Orgasm .87 .35 .73 .46     -.21 1.00 
Satisfaction 3.43 2.29 2.46 2.46 -.51** .46 
 
  *Significant at p<.05 (2-tailed) 
** Significant at p<.01 (2-tailed) 
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Table 6. Outcomes By Activity Using t-test for Equality of Means 
 
 
 Active Inactive   
 M SD M SD t-test p-value 
Desire .70 .47 .13 .34 -5.98** .000 
Arousal .70 .47 .08 .27 -7.03** .000 
Orgasm .86 .36 .00 .00 -4.06** .000 
Satisfaction 4.09 2.00 2.45 2.64 -2.92** .005 
 
  *Significant at p<.05 (2-tailed) 
** Significant at p<.01 (2-tailed) 
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Table 7. Logistic Regression Model Predicting Desire at 4 Months 
 
Variables B SE B Wald p value OR 
Age .025 .036 .464 .496 1.025 
Partner Status -.421 .758 .308 .579 .656 
Breast Cancer -.665 .816 .665 .415 .514 
CES-D -.259 .135 3.707 .054 .771 
PRO-CTCAE .081 .054 2.246 .134 1.084 
Baseline Desire 1.313 .874 2.258 .133 3.719 
Sexually active 2.543 .880 8.359 .004** 12.721 
 
*Significant at p<.05 (2-tailed) 
** Significant at p<.01 (2-tailed) 
All values represent final model statistics.   
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Table 8. Logistic Regression Model Predicting Arousal at 4 Months 
 
Variables B SE B Wald p value OR 
Age .027 .035 .614 .433 1.028 
Partner Status -.558 .755 .546 .460 .572 
CES-D -.138 .124 1.240 .265 .871 
PRO-CTCAE .045 .052 .730 .393 1.046 
Baseline Arousal .498 .848 .345 .557 1.646 
Sexually active -3.449 2.463 1.961 .001** .032 
 
*Significant at p<.05 (2-tailed) 
** Significant at p<.01 (2-tailed) 
All values represent final model statistics.   
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Table 9. Linear Regression Model Predicting Satisfaction at 4 Months 
 
Variable β t p value R R2 ΔR2 p value 
Step 1    .087 .008 .008 .784 
    Age .085 .732 .467     
    Partner Status -.012 -.111 .912     
Step 2    .260 .068 .060* .048 
   Depression -.239 -1.765 .083     
Step 3    .273 .075 .007 .502 
   Treatment Toxicity .137 1.030 .307     
Step 4    .555 .308 .234** .000 
   Baseline Satisfaction .453 3.872** .000     
Step 5    .564 .318 .010 .347 
   Sexual Activity .118 .948 .347     
 
*Significant at p<.05 (2-tailed) 
** Significant at p<.01 (2-tailed) 
Values in columns 2-4 (β, t, p) represent final model statistics.   
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Figure 1. Frequency Distribution of 4-Month Sexual Satisfaction Scores   
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